Highlights: -One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms -New Eluvia drug-eluting stent shows 94.4% primary patency rate at nine months -Michael Dake: Arch branded device -Andrew Holden: Bioresorbable stents -Profile: Janet Powell
[pdfviewer width=”100%” height=”940px” beta=”true”]http://vascularnews.com/wp-content/uploads/sites/7/2016/02/66-Vascular-News-EU.pdf[/pdfviewer]
